Transduction of peptide analogs of the small heat shock-related protein HSP20 inhibits intimal hyperplasia

Journal of Vascular Surgery

Volumn 40, Issue 1, 2004, Pages 106-114

  Tessier, Deron J ^a   Komalavilas, Padmini ^b,c   Liu, Bo ^d   Kent, Craig K ^d   Thresher, Jeffrey S ^b   Dreiza, Catherine M ^b   Panitch, Alyssa ^b   Joshi, Lokesh ^b   Furnish, Elizabeth ^b   Stone, William ^a   Fowl, Richard ^a   Brophy, Colleen M ^b,c  

^a MAYO CLINIC   (United States)

^b Arizona State University   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BIOMIMETIC MATERIAL; HEAT SHOCK PROTEIN 20; NORADRENALIN; PEPTIDE DERIVATIVE; SERINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CULTURE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; MUSCLE; MUSCLE RELAXATION; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS; RAT; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYNTHESIS; THICKNESS; VASOSPASM; VEIN GRAFT;

CELLS, CULTURED; GRAFT OCCLUSION, VASCULAR; HEAT-SHOCK PROTEINS; HSP20 HEAT-SHOCK PROTEINS; HUMANS; HYPERPLASIA; MYOCYTES, SMOOTH MUSCLE; ORGAN CULTURE TECHNIQUES; PHOSPHOPEPTIDES; PHOSPHOPROTEINS; SAPHENOUS VEIN; SPASM; TRANSDUCTION, GENETIC; TUNICA INTIMA;

EID: 3042533384     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2004.03.028     Document Type: Article

References (48)

1. LoGerfo F.W., Haudenschild C.C., Quist W.C. A clinical technique for prevention of spasm and preservation of endothelium in saphenous vein grafts. Arch Surg. 119:1984;1212-1214
2. LoGerfo F.W., Quist W.C., Cantelmo N.L., Haudenschild C.C. Integrity of vein grafts as a function of initial intimal and medial preservation. Circulation. 68:1983;II117-124
3. Spencer F.C. Bypass grafting for occlusive disease of the coronary arteries. Md State Med J. 20:1971;68-73
4. Varty K., Allen K.E., Bell P.R., London N.J. Infrainguinal vein graft stenosis. Br J Surg. 80:1993;825-833
5. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., Burton J.R. Coronary bypass graft fate and patient outcome angiographic follow-up of 5, 065 grafts related to survival and reoperation in 1, 388 patients during 25 years. J Am Coll Cardiol. 28:1996;616-626
6. Davies M.G., Hagen P.O. Pathophysiology of vein graft failure a review. Eur J Vasc Endovasc Surg. 9:1995;7-18
7. Engelse M.A., Lardenoye J.H., Neele J.M., Grimbergen J.M., De Vries M.R., Lamfers M.L., et al. Adenoviral activin a expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype. Circ Res. 90:2002;1128-1134
8. Beall A.C., Kato K., Goldenring J.R., Rasmussen H., Brophy C.M. Cyclic nucleotide-dependent vasorelaxation is associated with the phosphorylation of a small heat shock-related protein. J Biol Chem. 272:1997;11283-11287
9. Kato K., Goto G., Inaguma Y., Hasegawa K., Morishita R., Asano T. Purification and characterization of a 20-kDa protein that is highly homologous to alphaB-crystallin. J Biol Chem. 269:1994;15302-15309
10. Woodrum D.A., Brophy C.M., Wingard C.J., Beall A., Rasmussen H. Phosphorylation events associated with cyclic nucleotide-dependent inhibition of smooth muscle contraction. Am J Physiol. 277:1999;H931-939
11. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777
12. Dubey R.K. Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. J Pharmacol Exp Ther. 269:1994;402-408
13. Dubey R.K., Jackson E.K., Luscher T.F. Nitric oxide inhibits angiotensin II-mediated migration of rat aortic smooth muscle cells. J Clin Invest. 96:1995;141-149
14. Sayers R.D., Watt P.A., Muller S., Bell P.R., Thurston H. Endothelial cell injury secondary to surgical preparation of reversed and in situ saphenous vein bypass grafts. Eur J Vasc Surg. 6:1992;354-361
15. Cable D.G., Caccitolo J.A., Caplice N., O'Brien T., Simari R.D., Daly R.C., et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation. 100:1999;II392-396
16. Davies M.G., Klyachkin M.L., Dalen H., Svendsen E., Hagen P.O. Regression of intimal hyperplasia with restoration of endothelium-dependent relaxing factor-mediated relaxation in experimental vein grafts. Surgery. 114:1993;258-270. ; discussion 270-251
17. Fulton G.J., Davies M.G., Barber L., Gray J.L., Svendsen E., Hagen P.O. Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Eur J Vasc Endovasc Surg. 15:1998;279-289
18. Ohta S., Komori K., Yonemitsu Y., Onohara T., Matsumoto T., Sugimachi K. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit a limited biological effect as a result of the loss of medial smooth muscle cells. Surgery. 131:2002;644-653
19. Yu S.-M., Hung L.-M., Lin C.-C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation. 95:1997;1269-1277
20. Boerth N.J., Dey N.B., Cornwell T.L., Lincoln T.M. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J Vasc Res. 34:1997;245-259
21. Cornwell T.L., Arnold E., Boerth N.J., Lincoln T.M. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 267:1994;1405-1413
22. Itoh H., Yamamura S., Ware J.A., Zhuang S., Mii S., Liu B., et al. Differential effects of protein kinase C on human vascular smooth muscle cell proliferation and migration. Am J Physiol Heart Circ Physiol. 281:2001;H359-370
23. Inoue Y., Toga K., Sudo T., Tachibana K., Tochizawa S., Kimura Y., et al. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. Br J Pharmacol. 130:2000;231-241
24. Beppu M., Obayashi S., Aso T., Goto M., Azuma H. Endogenous nitric oxide synthase inhibitors in endothelial cells, endothelin-1 within the vessel wall, and intimal hyperplasia in perimenopausal human uterine arteries. J Cardiovasc Pharmacol. 39:2002;192-200
25. Masuda H., Goto M., Tamaoki S., Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol. 126:1999;211-218
26. Beall A., Bagwell D., Woodrum D., Stoming T.A., Kato K., Suzuki A., et al. The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation. J Biol Chem. 274:1999;11344-11351
27. Brophy C.M., Woodrum D.A., Pollock J., Dickinson M., Komalavilas P., Cornwell T.L., et al. cGMP-dependent protein kinase expression restores contractile function in cultured vascular smooth muscle cells. J Vasc Res. 39:2002;95-103
28. Kibbe M.R., Nie S., Yoneyama T., Hatakeyama K., Lizonova A., Kovesdi I., et al. Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery. 126:1999;323-329
29. Channon K.M., Qian H., George S.E. Nitric oxide synthase in atherosclerosis and vascular injury insights from experimental gene therapy. Arterioscler Thromb Vasc Biol. 20:2000;1873-1881
30. Yu H., Kumar S.R., Tang L., Terramani T.T., Rowe V.L., Wang Y., et al. Injury induced neointima formation and its inhibition by retrovirus-mediated transfer of nitride oxide synthase gene in an in-vitro human saphenous vein culture model. Atherosclerosis. 161:2002;113-122
31. Duckers H.J., Nabel E.G. Prospects for genetic therapy of cardiovascular disease. Med Clin North Am. 84:2000;199-213
32. Kalra M., Jost C.J., Severson S.R., Miller V.M. Adventitial versus intimal liposome-mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene. J Vasc Surg. 32:2000;1190-1200
33. Ibrahim J., Hughes A.D., Sever P.S. Action of angiotensin II on DNA synthesis by human saphenous vein in organ culture. Hypertension. 36:2000;917-921
34. Woodrum D., Pipkin W., Tessier D., Komalavilas P., Brophy C.M. Phosphorylation of the heat shock-related protein, HSP20, mediates cyclic nucleotide-dependent relaxation. J Vasc Surg. 37:2003;874-881
35. Flynn C.R., Komalavilas P., Tessier D., Thresher J., Niederkofler E.E., Dreiza C.M., et al. Transduction of biologically active motifs of the small heat shock- related protein, HSP20, leads to relaxation of vascular smooth muscle. Faseb J. 10:2003;1358-1360
36. Soyombo A.A., Angelini G.D., Newby A.C. Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J Thorac Cardiovasc Surg. 109:1995;2-12
37. Porter K.E., Dickinson T., London N.J. Inhibition of neointima formation in an organ culture of human saphenous vein a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition. J Vasc Surg. 34:2001;548-554
38. Ehsan A., Mann M.J., Dell'Acqua G., Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg. 121:2001;714-722
39. Yaffe M.B., Rittinger K., Volinia S., Caron P.R., Aitken A., Leffers H., et al. The structural basis for 14-3-3 phosphopeptide binding specificity. Cell. 91:1997;961-971
40. Yaffe M.B., Cantley L.C. Signal transduction. Grabbing phosphoproteins. Nature. 402:1999;30-31
41. Kreylos O, Max N, Crivelli S. ProtoShop: interactive design of protein structures. In: Moult J, Fidelis K, Zemla A, Hubbard T, editors. Proceedings of CASP5 - fifth meeting on the critical assessment of techniques for protein structure prediction; 2002 Dec 1-5; Pacific Grove, Calif. A213-4
42. Parmiter C, Furnish E, Komalavilas P, Brophy CM. Phospho-HSP20 peptide analogues cause actin depolymerization by altering the association of cofilin and 14-3-3. ASCB Abstract No. L 89. Proceedings of the 43rd Annual Meeting of the American Society of Cell Biology, 2003 Dec 13-17; San Francisco
43. Yaffe M.B., Rittinger K., Volinia S., Caron P.R., Aitken A., Leffers H., et al. The structural basis for 14-3-3 phosphopeptide binding specificity. Cell. 91:1997;961-971
44. Gohla A., Bokoch G.M. 14-3-3 regulates actin dynamics by stabilizing phosphorylated cofilin. Curr Biol. 12:2002;1704-1710
45. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572
46. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci. 21:2001;6000-6007
47. Takenobu T., Tomizawa K., Matsushita M., Li S.T., Moriwaki A., Lu Y.F., Matsui H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther. 1:2002;1043-1049
48. Schwarze S.R., Dowdy S.F. In vivo protein transduction intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci. 21:2000;45-48